Marker Therapeutics (MRKR) to Release Earnings on Monday

Marker Therapeutics (NASDAQ:MRKR) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Marker Therapeutics to post earnings of ($0.28) per share and revenue of $5.25 million for the quarter.

Marker Therapeutics Price Performance

Shares of MRKR opened at $1.24 on Monday. Marker Therapeutics has a 12-month low of $1.13 and a 12-month high of $5.99. The firm has a 50-day moving average price of $1.93 and a 200 day moving average price of $2.87.

Insider Activity

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms acquired 11,085 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, with a total value of $35,472.00. Following the purchase, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Insiders own 14.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MRKR. Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th. Canaccord Genuity Group began coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $8.00 target price for the company.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.